{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=11",
    "query": {
      "condition": "Relapse Leukemia",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 1826,
    "total_pages": 183,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T11:36:33.044Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00457860",
      "title": "Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Immunotoxin therapy",
          "type": "DRUG"
        },
        {
          "name": "CAT-8015 immunotoxin",
          "type": "DRUG"
        },
        {
          "name": "Biological therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Cambridge Antibody Technology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2007-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-04-17",
      "last_synced_at": "2026-11-07T11:36:33.044Z",
      "location_count": 3,
      "location_summary": "Beverly Hills, California • Indianapolis, Indiana • Bethesda, Maryland",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00457860"
    },
    {
      "nct_id": "NCT05244070",
      "title": "A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Lymphocytic, Chronic, B-Cell",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "BMS-986403",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2022-09-14",
      "completion_date": "2023-05-04",
      "has_results": false,
      "last_update_posted_date": "2023-07-18",
      "last_synced_at": "2026-11-07T11:36:33.044Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05244070"
    },
    {
      "nct_id": "NCT04109482",
      "title": "Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)"
      ],
      "interventions": [
        {
          "name": "MB-102",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mustang Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2020-02-17",
      "completion_date": "2023-05-17",
      "has_results": false,
      "last_update_posted_date": "2024-07-22",
      "last_synced_at": "2026-11-07T11:36:33.044Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Boston, Massachusetts • Durham, North Carolina + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04109482"
    },
    {
      "nct_id": "NCT04322383",
      "title": "Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hairy Cell Leukemia"
      ],
      "interventions": [
        {
          "name": "binimetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2021-01-07",
      "completion_date": "2028-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-07T11:36:33.044Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04322383"
    },
    {
      "nct_id": "NCT00251368",
      "title": "Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Myelocytic, Acute",
        "Acute Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "9-Aminocamptothecin (9-AC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "1995-01",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2011-03-10",
      "last_synced_at": "2026-11-07T11:36:33.044Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00251368"
    },
    {
      "nct_id": "NCT07347418",
      "title": "CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Acute Myeloid Leukemia (AML)",
        "Relapsed Acute Myeloid Leukemia (AML)",
        "Myelodysplastic Syndrome",
        "AML (Acute Myeloid Leukemia)"
      ],
      "interventions": [
        {
          "name": "CD64 CAR T Cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2026-09-10",
      "completion_date": "2032-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-11-07T11:36:33.044Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07347418"
    },
    {
      "nct_id": "NCT05440409",
      "title": "CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Leukemia, Acute Lymphoblastic",
        "Lymphoblastic Leukemia, Acute, Childhood"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "3 Years to 25 Years"
      },
      "enrollment_count": 57,
      "start_date": "2021-10-14",
      "completion_date": "2024-10-29",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-07T11:36:33.044Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05440409"
    },
    {
      "nct_id": "NCT03328104",
      "title": "Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoblastic Leukemia",
        "Lymphoblastic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Nelarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "2 Years to 29 Years"
      },
      "enrollment_count": 8,
      "start_date": "2018-07-24",
      "completion_date": "2023-06-29",
      "has_results": false,
      "last_update_posted_date": "2023-07-21",
      "last_synced_at": "2026-11-07T11:36:33.044Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • New York, New York • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03328104"
    },
    {
      "nct_id": "NCT00481871",
      "title": "Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed or Refractory Lymphoproliferative Malignancies",
        "Hodgkin's Lymphoma",
        "Peripheral T-cell Lymphoma",
        "B-cell Lymphoma",
        "Waldenstrom's Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Pralatrexate Injection",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Vitamin B12",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Folic Acid",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Acrotech Biopharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2007-05",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2020-01-07",
      "last_synced_at": "2026-11-07T11:36:33.044Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Stanford, California • Denver, Colorado + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00481871"
    },
    {
      "nct_id": "NCT00281814",
      "title": "Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases",
        "Psychosocial Effects of Cancer and Its Treatment"
      ],
      "interventions": [
        {
          "name": "psychosocial assessment and care",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2006-02-01",
      "completion_date": "2017-01-04",
      "has_results": false,
      "last_update_posted_date": "2018-01-26",
      "last_synced_at": "2026-11-07T11:36:33.044Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00281814"
    }
  ]
}